Literature DB >> 15781654

The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.

Einar K Rofstad1, Berit Mathiesen, Kristin Henriksen, Kristil Kindem, Kanthi Galappathi.   

Abstract

Cancer patients with recurrent local disease after radiation therapy have increased probability of developing regional and distant metastases. The mechanisms behind this observation were studied in the present work by using D-12 and R-18 human melanoma xenografts growing in preirradiated beds in BALB/c-nu/nu mice as preclinical models of recurrent primary tumors in humans. D-12 tumors metastasize to the lungs, whereas R-18 tumors develop lymph node metastases. Based on earlier studies, we hypothesized that metastasis was governed primarily by the proangiogenic factor interleukin-8 (IL-8) in D-12 tumors and by the invasive growth-promoting receptor urokinase-type plasminogen activator receptor (uPAR) in R-18 tumors. Pimonidazole was used as a hypoxia marker, and hypoxia, microvascular hotspots, and the expression of IL-8 and uPAR were studied by immunohistochemistry. The metastatic frequency was significantly higher in tumors in preirradiated beds than in control tumors in unirradiated beds, and it increased with the preirradiation dose. D-12 tumors showed increased fraction of hypoxic cells, increased fraction of IL-8-positive cells, and increased density of microvascular hotspots in preirradiated beds, and R-18 tumors showed increased fraction of hypoxic cells and increased fraction of uPAR-positive cells in preirradiated beds. Strong correlations were found between these parameters and metastatic frequency. IL-8 was up-regulated in hypoxic regions of D-12 tumors, and uPAR was up-regulated in hypoxic regions of R-18 tumors. Daily treatment with anti-IL-8 antibody (D-12) or anti-uPAR antibody (R-18) suppressed metastasis significantly. Our preclinical study suggests that primary tumors recurring after inadequate radiation therapy may show increased metastatic propensity because of increased fraction of hypoxic cells and hypoxia-induced up-regulation of metastasis-promoting gene products. Two possible mechanisms were identified: hypoxia may enhance metastasis by inducing neoangiogenesis facilitating hematogenous spread and by promoting invasive growth facilitating lymphogenous spread. The aggressive behavior of postirradiation local recurrences suggests that they should be subjected to curative treatment as early as possible to prevent further metastatic dissemination. Moreover, the possibility that patients with a high probability of developing local recurrences after radiation therapy may benefit from postirradiation treatment with antiangiogenic and/or anti-invasive agents merits clinical investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781654     DOI: 10.1158/0008-5472.CAN-04-3039

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Authors:  Mitomu Kioi; Hannes Vogel; Geoffrey Schultz; Robert M Hoffman; Griffith R Harsh; J Martin Brown
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

Review 2.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

Review 3.  Effects of irradiation on tumor cell survival, invasion and angiogenesis.

Authors:  Odysseas Kargiotis; Aliki Geka; Jasti S Rao; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

4.  CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia.

Authors:  Barbara Muz; Nilantha Bandara; Cedric Mpoy; Jennifer Sun; Kinan Alhallak; Feda Azab; Buck E Rogers; Abdel Kareem Azab
Journal:  Cancer Biol Ther       Date:  2019-10-01       Impact factor: 4.742

5.  Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Authors:  Kevin O Hicks; Bronwyn G Siim; Jagdish K Jaiswal; Frederik B Pruijn; Annie M Fraser; Rita Patel; Alison Hogg; H D Sarath Liyanage; Mary Jo Dorie; J Martin Brown; William A Denny; Michael P Hay; William R Wilson
Journal:  Clin Cancer Res       Date:  2010-08-20       Impact factor: 12.531

6.  A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.

Authors:  Jarrod D Predina; Brendan Judy; Zvi G Fridlender; Louis A Aliperti; Brian Madajewski; Veena Kapoor; Guanjun Cheng; Jon Quatromoni; Olugbenga Okusanya; Sunil Singhal
Journal:  Cancer Biol Ther       Date:  2012-05-23       Impact factor: 4.742

7.  Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting.

Authors:  Natsuko Imaizumi; Yan Monnier; Monika Hegi; René-Olivier Mirimanoff; Curzio Rüegg
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

Review 8.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cell Cycle       Date:  2009-04-04       Impact factor: 4.534

9.  Molecular mechanisms underlying postoperative peritoneal tumor dissemination may differ between a laparotomy and carbon dioxide pneumoperitoneum: a syngeneic mouse model with controlled respiratory support.

Authors:  Sachiko Matsuzaki; Nicolas Bourdel; Claude Darcha; Pierre J Déchelotte; Jean-Etienne Bazin; Jean-Luc Pouly; Gérard Mage; Michel Canis
Journal:  Surg Endosc       Date:  2008-07-12       Impact factor: 4.584

10.  Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.

Authors:  Ingeborg M Bachmann; Rita G Ladstein; Oddbjørn Straume; George N Naumov; Lars A Akslen
Journal:  BMC Cancer       Date:  2008-12-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.